The FDA has approved enflonsia, a fixed-dose monoclonal antibody, for preventing RSV lower respiratory tract disease in infants during their first season.
New research found that first-time mothers experienced substantial sleep disruption for more than 3 months after childbirth, even as total sleep time gradually recovered.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
A population-based study discussed at APAAM25 links full sibling history to increased risk of postpartum psychosis – but notes the absolute risk remains low.
After showing higher efficacy and a comparable safety profile to Spikevax, the FDA has approved Moderna’s mNEXSPIKE COVID-19 vaccine for high-risk patients.